close
close
Filament Health announces financial results and operational highlights in the first quarter of 2025

Filament Health announces financial results and operational highlights in the first quarter of 2025

by

Vancouver, BCPresent May 8, 2025 / CNW/ – Filament Health Corp. (OTCQB: FlHLF) (CBOE: FH) (FSE: 7QS) (“Filament” or “Company”), a natural company for natural psychedelic drug development that has published its financial results and operational highlights for the first quarter for the final period March 31, 2025.

Filament Health Logo (CNW Group/Filament Health Corp.)

“In this quarter, we are pleased to see positive data from a clinical study that our botanical psilocybin candidate Pex010 for alcohol consumer disorders at the Psychiatric Center for Copenhagen examined remarkable operational developments,” said, “said,” “said,” “,” Benjamin Light TertourCo -founder and Chief Executive Officer at Filament Health. “We were also encouraged by successfully completing a sensible fundraising round. This progress shows the resilience and the commitment of our team to promote our mission.”

Newer and Q1 2025 financial and operational highlights:

  • To April 9, 2025The company terminated the FDA approval of a clinical phase -2 University of Pennsylvania.

  • To April 9, 2025The company concluded a financing of 960,000 US dollars Further to grant units that consisted of a secure convertible bonds of the company and an arrest warrant.

  • To March 17, 2025The company announced that a license partner who examined the effects of its botanical psilocybin candidate PEX010 for the treatment of alcohol consumption disorders (“AUD”) was published in the Journal of Psychopharmacology, in which the security and effectiveness of reducing alcohol consumption were determined with alcohol consumption.

  • To January 21, 2025The company terminated the delivery of botanical psilocybin to the University of Wisconsin-Madison Clinical studies approved for the examination of two US foods and drugs that examine the effects of psilocybin on neuroplasticity.

  • Cash and cash equivalents from $ 130.441 away March 31, 2025;

  • Cash used for operating activities $ 221,755 and overall income of $ 103,480.

Special assembly

Held at a special shareholder session May 6, 202599.625 percent of the votes were submitted in favor of the voluntary loss of the company's ordinary shares from CBOE Canada. This strong support reflects the orientation of the shareholders on the strategic orientation of the company and the ongoing efforts to reduce operating costs. The company is in active discussions with CBOE Canada about the Listing and will share further information, e.g.

Leave a Comment